Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers (Q35023456)

5 August 2017

title

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers (English)

1 reference

5 August 2017

Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers (English)

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.33.9473

30 November 2024

1

Tanios Bekaii-Saab

1 reference

5 August 2017

2

Mitch A. Phelps

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

30 November 2024

17

Matthew D. Ringel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

30 November 2024

author name string

Xiaobai Li

3

1 reference

5 August 2017

Motoyasu Saji

4

1 reference

5 August 2017

Laura Goff

5

1 reference

5 August 2017

John Sae Wook Kauh

6

1 reference

5 August 2017

Stephanie Balsom

8

1 reference

5 August 2017

Catherine Balint

9

1 reference

5 August 2017

Ryan Liersemann

10

1 reference

5 August 2017

Mark Bloomston

12

1 reference

5 August 2017

William Marsh

13

1 reference

5 August 2017

Gilian Ellison

15

1 reference

5 August 2017

Michael Grever

16

1 reference

5 August 2017

Bert H. O'Neil

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

30 November 2024

Vasily V. Vasko

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

30 November 2024

L. Austin Doyle

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

30 November 2024

Miguel A. Villalona-Calero

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

30 November 2024

language of work or name

English

0 references

publication date

25 April 2011

1 reference

full work available at URL

5 August 2017

https://europepmc.org/articles/pmc3107751?pdf=render

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

https://europepmc.org/articles/PMC3107751

30 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

https://europepmc.org/articles/PMC3107751?pdf=render

30 November 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

https://doi.org/10.1200/jco.2010.33.9473

30 November 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21519026

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.33.9473

30 November 2024

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.33.9473

Journal of Clinical Oncology

30 November 2024

published in

1 reference

5 August 2017

volume

29

1 reference

5 August 2017

issue

17

1 reference

5 August 2017

page(s)

2357-2363

1 reference

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

MEK1 mutations confer resistance to MEK and B-RAF inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

8 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Systemic therapy for biliary tract cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Targeting BRAF in thyroid cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Phase II study of erlotinib in patients with advanced biliary cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

BRAF mutation predicts sensitivity to MEK inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Mouse models of K-ras-initiated carcinogenesis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

The RAF proteins take centre stage

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

The V599E BRAF mutation is uncommon in biliary tract cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Conferring specificity on the ubiquitous Raf/MEK signalling pathway

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Mutations of the BRAF gene in human cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Genes and viruses in hepatobiliary neoplasia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Association of IL-6 gene polymorphisms with cachexia susceptibility and survival time of patients with pancreatic cancer.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

Pharmacologic inhibitors of MKK1 and MKK2.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3107751

The role of cytokines in cancer cachexia

25 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21519026

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21519026

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biochimica et Biophysica Acta

8

1756

145

Janssen KP

2005

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.33.9473

Annals of clinical laboratory science

30 November 2024

27

38

113

Zhang D

2008

1 reference

https://api.crossref.org/works/10.1200/JCO.2010.33.9473

30 November 2024

Identifiers

1 reference

release_whkywlxwujc2xbinrn36a3iw54

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/whkywlxwujc2xbinrn36a3iw54

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

3107751

1 reference

5 August 2017

1 reference